Advanced search
Publication Cover
OncoImmunology Volume 7, 2018 - Issue 2
Submit an article Journal homepage
2,237
Views
28
CrossRef citations to date
0
Altmetric
Original Research

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy

Shamaila Munir AhmadCenter for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark
,
Evelina MartinenaiteCenter for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark
,
Morten HolmströmCenter for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark;Department of Hematology, Zealand University Hospital, DK-4000Roskilde, DenmarkORCID Iconhttps://orcid.org/0000-0002-3764-8578
ORCID Icon,
Mia Aaboe JørgensenCenter for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark
,
Özcan MetCenter for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark;Department of Oncology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark;Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
,
Claudia NastasiDepartment of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
,
Uffe KlausenCenter for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730Herlev, DenmarkORCID Iconhttps://orcid.org/0000-0001-8932-0374
ORCID Icon,
Marco DoniaCenter for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark;Department of Oncology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark
,
Lars Møller PedersenDepartment of hematology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark
,
Lars MunksgaardDepartment of Hematology, Zealand University Hospital, DK-4000Roskilde, Denmark
,
Niels ØdumDepartment of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
,
Anders WoetmannDepartment of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
,
Inge Marie SvaneCenter for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark;Department of Oncology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark
&
Mads Hald AndersenCenter for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark;Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, DenmarkCorrespondence[email protected]
 show all
Article: e1390641 | Received 17 Aug 2017, Accepted 05 Oct 2017, Published online: 01 Nov 2017

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.